





Orchid Chemicals & Pharmaceuticals Limited							
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2012							
Rs. lakhs							
S. No.	Particulars	Standalone					
		Unaudited				Audited	
		Three months ended 31-Dec-12	Three months ended 30-Sep-12	Three months ended 31-Dec-11	Nine months ended 31-Dec-12	Nine months ended 31-Dec-11	Year ended 31-Mar-12
1	Income from Operations						
	a) Net Sales / Income from Operations (Net of Excise Duty)	31352.96	33054.81	46380.79	95970.92	124979.06	170170.80
	b) Other Operating Income	-	-	697.12	4159.80	2406.96	6293.47
	Total income from operations (Net) (1+2)	31352.96	33054.81	47077.91	100130.82	127386.02	176464.27
2	Expenses						
	a) Cost of materials consumed	9352.92	15202.02	21325.79	34748.23	61667.71	80241.50
	b) Purchases of stock-in-trade	1370.12	1420.27	926.64	4328.71	3491.47	4546.38
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	6613.47	(914.03)	(1839.40)	12903.59	(7326.83)	(6201.86)
	d) Employee benefit expense	4084.56	4130.37	4024.33	11976.72	11459.72	15464.59
	e) Depreciation / Amortisation	3906.01	3955.09	3736.13	11852.36	10864.19	14905.56
	f) Other Expenses	7596.62	9272.27	9775.51	24313.35	25873.18	41242.32
	Total Expenses	32923.70	33065.99	37949.00	100122.96	106029.44	150198.49
3	Profit/(Loss) from operations before other income, finance costs, exceptional items (1-2)	(1570.74)	(11.18)	9128.91	7.86	21356.58	26265.78
4	Other Income	(0.00)	1.31	-	1.31	1.30	1.59
5	Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)	(1570.74)	(9.87)	9128.91	9.17	21357.88	26267.37
6	Finance costs	7069.30	7647.05	4945.31	21848.95	12026.74	17905.29
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	(8640.04)	(7656.92)	4183.60	(21839.78)	9331.14	8362.08
8	Exceptional Items	(559.18)	4621.98	(4906.81)	3254.76	(8159.41)	(8388.14)
9	Profit/(Loss) from ordinary activities before Tax (7+8)	(9199.22)	(3034.94)	(723.21)	(18585.02)	1171.73	(26.06)
10	Tax expenses						
	- Current Tax & Deferred Tax	(1963.45)	(1040.33)	289.26	(4274.44)	720.08	(2337.22)
11	Net Profit/(Loss) from ordinary activities after Tax (9-10)	(7235.77)	(1994.61)	(1012.47)	(14310.58)	451.65	2311.16
12	Extraordinary item (net of tax expenses Rs.nil)	-	-	-	-	8000.00	8000.00
13	Net Profit/(Loss) for the period (11+12)	(7235.77)	(1994.61)	(1012.47)	(14310.58)	8451.65	10311.16
14	Paid-up Equity Share Capital (Face value of Rs.10/- each)	7045.21	7045.21	7044.21	7045.21	7044.21	7044.21
15	Reserves excluding Revaluation Reserves	-	-	-	-	-	112410.89
16	Earnings per share (EPS) before extra-ordinary items of Rs.10/- each*						
	- Basic Rs.	(10.27)	(2.83)	(1.44)	(20.31)	0.64	3.28
	- Diluted Rs.	(10.27)	(2.83)	(1.44)	(20.31)	0.52	3.24
17	Earnings per share (EPS) after extra-ordinary items of Rs.10/- each*						
	- Basic Rs.	(10.27)	(2.83)	(1.44)	(20.31)	12.00	14.64
	- Diluted Rs.	(10.27)	(2.83)	(1.44)	(20.31)	9.81	14.46
A	PARTICULARS OF SHAREHOLDING						
1	Public Shareholding						
	- Number of equity shares	47611295	47611295	47601295	47611295	47601295	47601295
	- Percentage of Shareholding	67.58	67.58	67.58	67.58	67.58	67.57
2	Promoters and Promoter group shareholding						
a.	Pledged / Encumbered						
	- Number of shares	17818645	17676037	18260383	17818645	18260383	17060383
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	78.01	77.39	79.95	78.01	79.95	74.69
	- Percentage of shares (as a % of the total share capital of the company)	25.29	25.09	25.92	25.29	25.92	24.22
b.	Non - Encumbered						
	- Number of shares	5022136	5164744	4580398	5022136	4580398	5780398
	- Percentage of shares (as a % of the total shareholding of the promoter and promoter group)	21.99	22.61	20.05	21.99	20.05	25.31
	- Percentage of shares (as a % of the total share capital of the company)	7.13	7.33	6.50	7.13	6.50	8.21



Handwritten signature



B INVESTOR COMPLAINTS		3 Months ended 31-Dec-2012
Pending at the beginning of the quarter		- NIL -
Received during the quarter		25
Disposed off during the quarter		25
Remaining unresolved at the end of the quarter.		- NIL -
* EPS for the period (except for the year ended on March 31, 2012) is not annualised		
1	The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 13, 2013 and have been subjected to limited review by the Statutory Auditors in terms of Clause 41 of the Listing Agreement.	
2	Exceptional items for the nine months ended December 31, 2012 represents profit on sale of Investments in the Joint Venture in China of Rs. 5333.76 lakhs (Previous period - Rs.NIL), exchange loss on FCCBs / FCTLs of Rs.2079 lakhs (Corresponding quarter - Loss of Rs. 7029.70 lakhs). Exceptional Items for this quarter includes exchange loss on FCCBs / FCTLs of Rs. 766.46 lakhs corresponding quarter - Loss Rs. 4906.81 lakhs). One time closure cost of Alathur Plant for the quarter ended December 2012 is Rs. NIL (Previous period - Rs.1129.71 lakhs). The Company had exercised the option provided under the Amendment to the Companies (Accounting Standards) Amendments Rules, 2006 dated March 31, 2009. The Ministry of Corporate Affairs vide notification dated 29th December 2011 has extended the amortisation of gains or losses arising on reporting of Foreign Currency Monetary items over the balance period of such long term asset / liability. Accordingly Exchange Loss on long term foreign currency loans have been amortised over the balance period of such loans. The amount remaining to be amortized in the financial statements as at December 31, 2012 on account of exercising the above option is Rs.9383.55 lakhs (Corresponding period ended - Rs.7669.37 lakhs).	
3	During the Previous quarter the Company has entered into Business Transfer Agreement with Hospira Healthcare India Limited., for the sale and transfer of Orchid's Pencillin and Penem API Business and the API facility located in Aurangabad (Maharashtra). Together with associated process R&D Infrastructred locate in Chennai. The requisite approvals have already been obtained by Hospira Healthcare India Limited., during this quarter. The transaction is expected to be completed before March 31, 2013.	
4	The Company is operating in single segment (I.e) "Pharmaceuticals".	
5	Previous period figures have been regrouped wherever necessary.	
For and on behalf of the Board		
 K Raghavendra Rao Chairman & Managing Director		
Place : Chennai		
Date : February 13, 2013		



BSE: 524372 NSE: ORCHIDCHEM Bloomberg: OCP@IN Reuters: ORCD.BO

Q3 FY13 Earnings

Chennai, India – February 13, 2013

Orchid Pharma registers turnover of Rs 322 crore in Q3 FY13

Financial highlights for Quarter ended December 31, 2012 (Q3 FY13)

Earnings on consolidated basis


- Revenue of Rs 322 crore (US\$ 58.5 million) in Q3 FY13 versus Rs 496.8 crore (US\$ 90.3 million) in Q3 FY12
- EBITDA of Rs 21.6 crore (US\$ 3.9 million) in Q3 FY13 versus Rs 129.0 crore (US\$ 23.5 million) in Q3 FY12
- Loss before Tax of Rs 88.7 crore (US\$ 16.1 million) in Q3 FY13 compared to a profit before tax of Rs 41.1 crore (US\$ 7.5 million) during Q3 FY12
- At the net level, the company registered a loss (after exceptional item loss of Rs 5.6 crore) of Rs 74.7 crore (US\$ 13.6 million) in Q3 FY13 compared to a loss of Rs 11.06 crore (US\$ 2.0 million) during Q3 FY12

Financial highlights for 9-mths ended December 31, 2012

Earnings on consolidated basis

- Revenue of Rs 1107.1 crore (US\$ 201.3 million) in the 9-months ended December 31, 2012 versus Rs 1411.8 crore (US\$ 256.7 million) in the corresponding period of last fiscal
- EBITDA of Rs 113.1 crore (US\$ 20.6 million) in the 9-months ended December 31, 2012 versus Rs 324.1 crore (US\$ 58.9 million) in the same period of last fiscal
- Loss before Tax (before exceptional item loss of Rs 20.8 crore / extraordinary item gain of Rs 53.3 crore) of Rs 227.6 crore (US\$ 41.4 million) in the 9-months ended December 31, 2012 compared to a profit before tax of Rs 91.9 crore (US\$ 16.7 million) during the corresponding period of last fiscal
- Net loss after Tax (after exceptional item loss of Rs 20.8 crore / extraordinary item gain of Rs 53.3 crore) of Rs 152.7 crore (US\$ 27.8 million) in the 9-months ended December 31, 2012 compared to a net profit of Rs 82.2 crore (US\$ 14.9 million) registered during the same period last fiscal

'Orchid Towers', #313, Valluvar Kottam High Road, Nungambakkam, Chennai 600 034 INDIA





From the Chairman & Managing Director

"The overall performance of the company continues to witness pressure due to the tight working capital levels and debt leverage. We are working on completing the transfer of our Penicillin & Carbapenem business to Hospira and will see a significantly deleveraged position from the deal proceeds leading to improved performance in the quarters to come", said Mr K Raghavendra Rao, Chairman & Managing Director, Orchid Chemicals & Pharmaceuticals Ltd.

* 1 US\$ = Rs 55

For ORCHID CHEMICALS &
PHARMACEUTICALS LTD.


Chairman & Managing Director

'Orchid Towers', #313, Valluvar Kottam High Road, Nungambakkam, Chennai 600 034 INDIA

SNB ASSOCIATES

CHARTERED ACCOUNTANTS

12, 3rd Floor, Gemini Parsn Complex, 121 Mount Road, Chennai - 600 006.

AUDITORS' REPORT**TO THE BOARD OF DIRECTORS OF
ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED****ON LIMITED REVIEW OF UNAUDITED FINANCIAL RESULTS
FOR THE PERIOD ENDED DECEMBER 31, 2012**

We have reviewed the accompanying statement of unaudited financial results of **ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED** ("the Company") for the period ended 31st December 2012 except for the disclosures regarding "Public Shareholding" and "Promoter and Promoter Group Shareholding", which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is disclosed, or that it contains any material misstatements.

For SNB ASSOCIATES
Chartered Accountants
Firm Registration No. 015682N

Date: 13th February 2013
Place: Chennai



B. Mahalingam
B. Mahalingam
Partner

Membership No. 210408



Orchid Chemicals
& Pharmaceuticals Limited


STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2012

Rs. lakhs


S. No.	Particulars	Standalone					
		Unaudited					Audited
		Three months ended 31-Dec-12	Three months ended 30-Sep-12	Three months ended 31-Dec-11	Nine months ended 31-Dec-12	Nine months ended 31-Dec-11	Year ended 31-Mar-12
1	Income from Operations						
	a) Net Sales / Income from Operations (Net of Excise Duty)	31352.96	33054.81	46380.79	95970.92	124979.06	170170.80
	b) Other Operating Income	-	-	697.12	4159.90	2406.96	6293.47
	Total income from operations (Net) (1+2)	31352.96	33054.81	47077.91	100130.82	127386.02	176464.27
2	Expenses						
	a) Cost of materials consumed	9352.92	15202.02	21325.79	34748.23	61667.71	80241.50
	b) Purchases of stock-in-trade	1370.12	1420.27	926.64	4328.71	3491.47	4546.38
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	6613.47	(914.03)	(1839.40)	12903.59	(7326.83)	(6201.86)
	d) Employee benefit expense	4084.56	4130.37	4024.33	11976.72	11459.72	15464.59
	e) Depreciation / Amortisation	3906.01	3955.09	3736.13	11852.36	10864.19	14905.56
	f) Other Expenses	7596.62	9272.27	9775.51	24313.35	25873.18	41242.32
	Total Expenses	32923.70	33065.99	37949.00	100122.96	106029.44	150198.49
3	Profit/(Loss) from operations before other income, finance costs, exceptional items (1-2)	(1570.74)	(11.18)	9128.91	7.86	21356.58	26265.78
4	Other Income	(0.00)	1.31	-	1.31	1.30	1.59
5	Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)	(1570.74)	(9.87)	9128.91	9.17	21357.88	26267.37
6	Finance costs	7069.30	7647.05	4945.31	21848.95	12026.74	17905.29
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	(8640.04)	(7656.92)	4183.60	(21839.78)	9331.14	8362.08
8	Exceptional Items	(559.18)	4621.98	(4906.81)	3254.76	(8159.41)	(8388.14)
9	Profit/(Loss) from ordinary activities before Tax (7+8)	(9199.22)	(3034.94)	(723.21)	(18585.02)	1171.73	(26.06)
10	Tax expenses						
	- Current Tax & Deferred Tax	(1963.45)	(1040.33)	289.26	(4274.44)	720.08	(2337.22)
11	Net Profit/(Loss) from ordinary activities after Tax (9-10)	(7235.77)	(1994.61)	(1012.47)	(14310.58)	451.65	2311.16
12	Extraordinary item (net of tax expenses Rs.nil)	-	-	-	-	8000.00	8000.00
13	Net Profit/(Loss) for the period (11+12)	(7235.77)	(1994.61)	(1012.47)	(14310.58)	8451.65	10311.16
14	Paid-up Equity Share Capital (Face value of Rs.10/- each)	7045.21	7045.21	7044.21	7045.21	7044.21	7044.21
15	Reserves excluding Revaluation Reserves	-	-	-	-	-	112410.89
16	Earnings per share (EPS) before extra-ordinary items of Rs.10/- each*						
	- Basic Rs.	(10.27)	(2.83)	(1.44)	(20.31)	0.64	3.28
	- Diluted Rs.	(10.27)	(2.83)	(1.44)	(20.31)	0.52	3.24
17	Earnings per share (EPS) after extra-ordinary items of Rs.10/- each*						
	- Basic Rs.	(10.27)	(2.83)	(1.44)	(20.31)	12.00	14.64
	- Diluted Rs.	(10.27)	(2.83)	(1.44)	(20.31)	9.81	14.46
A	PARTICULARS OF SHAREHOLDING						
1	Public Shareholding						
	- Number of equity shares	47611295	47611295	47601295	47611295	47601295	47601295
	- Percentage of Shareholding	67.58	67.58	67.58	67.58	67.58	67.57
2	Promoters and Promoter group shareholding						
a.	Pledged / Encumbered						
	- Number of shares	17818645	17676037	18260383	17818645	18260383	17060383
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	78.01	77.39	79.95	78.01	79.95	74.69
	- Percentage of shares (as a % of the total share capital of the company)	25.29	25.09	25.92	25.29	25.92	24.22
b.	Non - Encumbered						
	- Number of shares	5022136	5164744	4580398	5022136	4580398	5780398
	- Percentage of shares (as a % of the total shareholding of the promoter and promoter group)	21.99	22.61	20.05	21.99	20.05	25.31
	- Percentage of shares (as a % of the total share capital of the company)	7.13	7.33	6.50	7.13	6.50	8.21

/ CERTIFIED TRUE COPY /

For ORCHID CHEMICALS & PHARMACEUTICALS LTD.






B INVESTOR COMPLAINTS		3 Months ended 31-Dec-2012
Pending at the beginning of the quarter		- NIL -
Received during the quarter		25
Disposed off during the quarter		25
Remaining unresolved at the end of the quarter		- NIL -
* EPS for the period (except for the year ended on March 31, 2012) is not annualised		
1	The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 13, 2013 and have been subjected to limited review by the Statutory Auditors in terms of Clause 41 of the Listing Agreement.	
2	Exceptional items for the nine months ended December 31, 2012 represents profit on sale of Investments in the Joint Venture in China of Rs. 5333.76 lakhs (Previous period - Rs.NIL), exchange loss on FCCBs / FCTLs of Rs.2079 lakhs (Corresponding quarter - Loss of Rs. 7029.70 lakhs). Exceptional items for this quarter includes exchange loss on FCCBs / FCTLs of Rs. 766.46 lakhs corresponding quarter - Loss Rs. 4906.81 lakhs). One time closure cost of Alathur Plant for the quarter ended December 2012 is Rs. NIL (Previous period - Rs.1129.71 lakhs). The Company had exercised the option provided under the Amendment to the Companies (Accounting Standards) Amendments Rules, 2006 dated March 31, 2009. The Ministry of Corporate Affairs vide notification dated 29th December 2011 has extended the amortisation of gains or losses arising on reporting of Foreign Currency Monetary items over the balance period of such long term asset / liability. Accordingly Exchange Loss on long term foreign currency loans have been amortised over the balance period of such loans. The amount remaining to be amortized in the financial statements as at December 31, 2012 on account of exercising the above option is Rs.9383.55 lakhs (Corresponding period ended - Rs.7669.37 lakhs).	
3	During the Previous quarter the Company has entered into Business Transfer Agreement with Hospira Healthcare India Limited., for the sale and transfer of Orchid's Pencillin and Penem API Business and the API facility located in Aurangabad (Maharashtra). Together with associated process R&D Infrastructred locate in Chennai. The requisite approvals have already been obtained by Hospira Healthcare India Limited., during this quarter. The transaction is expected to be completed before March 31, 2013.	
4	The Company is operating in single segment (i.e) "Pharmaceuticals".	
5	Previous period figures have been regrouped wherever necessary.	
		For and on behalf of the Board
		 K Raghavendra Rao Chairman & Managing Director
Place : Chennai		
Date : February 13, 2013		

/CERTIFIED TRUE COPY/

For ORCHID CHEMICALS &
PHARMACEUTICALS LTD.


Executive Vice President - Finance & Secretary

